PCM
RNAC icon

Pinz Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Pinz Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-353
Closed -$14K – 163
2022
Q2 		$14K Buy
+353
New +$10.5K 0.01% 219
2021
Q3 		– Sell
-850
Closed -$107K – 353
2021
Q2 		$107K Buy
+850
New +$101K 0.03% 239

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Pinz Capital Management's RNAC Position: Q3 2022 in Review

Pinz Capital Management sold out of Cartesian Therapeutics (RNAC) in Q3 2022, closing a stake of 353 shares — an estimated $14K sold.

Pinz Capital Management first reported a position in RNAC in Q2 2021 and held it in 2 quarters. The position peaked at $107K in Q2 2021. 96 funds tracked by Wall St. Rank hold RNAC as of Q3 2022.

  • Pinz Capital Management reported no remaining Cartesian Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Pinz Capital Management sold 353 Cartesian Therapeutics shares in Q3 2022, an estimated $14K.
  • Pinz Capital Management first reported a position in Cartesian Therapeutics in Q2 2021 and held it in 2 quarters.
  • Pinz Capital Management's Cartesian Therapeutics position peaked at $107K in Q2 2021.
  • 96 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2022.

Based on Pinz Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.